IP Library Granted Patent US 10,253,373
Granted Patent B2
US 10,253,373 · App. 15/591,896 · Granted Apr 9, 2019

Identification of tumor-associated markers for diagnosis and therapy

Inventors: Ugur Sahin (Mainz, DE); Özlem Türeci (Mainz, DE); Michael Koslowski (Mainz, DE)
Assignee: BIONTECH AG
C12Q1/6886C07K14/4748C07K16/30C12Q2600/118C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,253,373
App. No.
15/591,896
Granted
Apr 9, 2019
Kind
B2
Abstract

The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.

Claims (9)

1. A method of detecting a nucleic acid sequence consisting of SEQ ID NO: 44 in a cancer cell, wherein the method comprises the steps of:

detecting the presence of or determining the quantity of the nucleic acid sequence consisting of SEQ ID NO: 44 expressed in the cancer cell in a biological sample comprising tissue isolated from a patient, wherein

the detecting or determining comprises (i) contacting the biological sample with an agent that binds specifically to the nucleic acid, and (ii) detecting the formation of or determining the quantity of a complex between the agent and the nucleic acid, wherein said agent is an oligonucleotide or polynucleotide that hybridizes specifically to the nucleic acid or to the complementary nucleic acid sequence;

and

wherein said cancer cell is from a cancer or tumor selected from the group consisting of ovarian cancer, colorectal cancer, lung cancer, prostate cancer, melanoma, and cervical cancer.

2. The method of claim 1 , wherein the method comprises detection of the presence of or determination of the quantity of nucleic acid in a first sample at a first point in time and in a further sample at a second point in time.

3. The method of claim 1 , wherein the agent is labeled in a detectable manner.

4. The method of claim 1 , wherein tissue is from a tissue biopsy.

5. The method of claim 1 , wherein the detecting or determining comprises real-time reverse-transcription polymerase chain reaction (RT-PCR).

Assignments (3)
CHANGE OF NAME Recorded Jul 22, 2025
From: BIONTECH AG
To: BIONTECH SE
Reel/Frame 072170/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2017
From: SAHIN, UGUR; TÜRECI, ÖZLEM; KOSLOWSKI, MICHAEL
To: GANYMED PHARMACEUTICALS AG; JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
Reel/Frame 043170/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2017
From: GANYMED PHARMACEUTICALS AG
To: BIONTECH AG
Reel/Frame 043170/0899 →
Priority Claims (1)
EP 07020730 · Oct 23, 2007 · regional
Continuity (5)
Division 15003530 · Jan 21, 2016
Division 14158953 · Jan 20, 2014
Continuation 12765251 · Apr 22, 2010
Continuation PCTEP2008008924 · Oct 22, 2008
Related Publication 20170314078A1 · Nov 2, 2017